Academic Tags
Academic Tags > Tag based links for Credits
The following links have been tagged credits by users just like you, because these resources are off-site we cannot guarantee the accuracy or quality of any third-party information.
- ENVIRONMENT:
Ocean Iron
Fertilization-
-Moving
Forward in a
Sea of
Uncertainty: Science, Vol.
319, No. 5860.
(11 January
2008),
162.10.1126/sc
ience.1154305K
en Buesseler,
Scott Doney,
David Karl,
Philip Boyd,
Ken Caldeira,
Fei Chai,
Kenneth Coale,
Hein de Baar,
Paul
Falkowski,
Kenneth
Johnson,
Richard
Lampitt,
Anthony
Michaels, SWA
Naqvi, Victor
Smetacek,
Shigenobu
Takeda, Andrew
Watson
Source: Science, Vol. 319, No. 5860. (11 January 2008), 162. - Market watch: Nature, Vol.
445, No. 7128.
(07 February
2007), pp.
585-585.Quirin
Schiermeier
Source: Nature, Vol. 445, No. 7128. (07 February 2007), pp. 585-585. - Emissions
trading: The
carbon game: Nature, Vol.
432, No. 7015.
(18 November
2004), pp.
268-270.Michae
l Hopkin
Source: Nature, Vol. 432, No. 7015. (18 November 2004), pp. 268-270. - Is the global
carbon market
working?: Nature, Vol.
445, No. 7128.
(07 February
2007), pp.
595-596.Michae
l Wara
Source: Nature, Vol. 445, No. 7128. (07 February 2007), pp. 595-596. - Funding
pharmaceutical
innovation
through direct
tax credits: Health
Economics,
Policy and
Law, Vol. 2,
No. 03.
(2007), pp.
267-284.Rising
pharmaceutical
prices,
increasing
demand for
more effective
innovative
drugs and
growing public
outrage have
heightened
criticism of
the
pharmaceutical
industry. The
public debate
has focused on
drug prices
and access. As
a consequence,
the patent
system is
being
reexamined as
an efficient
mechanism for
encouraging
pharmaceutical
innovation and
drug
development.
We propose an
alternative to
the existing
patent system,
instead
rewarding the
innovating
firm with
direct tax
credits in
exchange for
marginal cost
pricing. This
concept is
based on the
fundamental
assumption
that
innovation
that benefits
society at
large may be
financed
publicly. As
an industry
which produces
a social good
characterized
by high fixed
costs, high
information
and regulatory
costs, and
relatively low
marginal costs
of production,
pharmaceutical
s are
well-suited to
such a
mechanism.
Under this
proposal, drug
prices fall,
consumer
surplus
increases,
access is
enhanced, and
the incentives
to innovate
are
preserved.Kris
tina Lybecker,
Robert Freeman
Source: Health Economics, Policy and Law, Vol. 2, No. 03. (2007), pp. 267-284.
If you would like to find additional social bookmark based links on the topic of credits we recommend the Open Tag Directory > Credits. If you would like to find related tags we recommend Tag Patterns > Credits.
